Page 2 - Staff Neurologist News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesEdna kaplanRobertj foxJessica breuAlexandra herrmannPaula schwartzDaniel vittMellen centerAmericas committee for treatmentResearch in multiple sclerosisNeurological instituteImmunic incExchange commissionDistribution servicesRx communications groupPresents data from phase

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesAlexandra herrmannDaniel vittPaula schwartzEdna kaplanRobertj foxJessica breuNeurological instituteImmunic incAmericas committee for treatmentExchange commissionMellen centerResearch in multiple sclerosisPresents data from phaseVidofludimus calciumAmericas committee

Immunic to Participate in Investor and Scientific Conferences in February

NEW YORK, Feb. 1, 2024 /PRNewswire/ Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and.

United statesNoord hollandPaula schwartzBiocapital europeJessica breuEdna kaplanAlexandra herrmannDaniel vittRobertj foxExchange commissionRx communications groupNeurological instituteMellen centerImmunic incChief executive officerVice president investor relations

Immunic Presents Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS Meeting

NEW YORK - Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that.

United statesRobertj foxDaniel vittJessica breuMellen centerNeurological instituteImmunic incExchange commissionStaff neurologistMultiple sclerosisCoordinating investigatorChief executive officerNeurofilament light chainVidofludimus calciumPoster numberPrivate securities litigation reform act

Immunic (IMUX) Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic (IMUX) Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel vittRobertj foxMellen centerNeurological instituteImmunic incStaff neurologistMultiple sclerosisCleveland clinicCoordinating investigatorChief executive officerNeurofilament light chainVidofludimus calciumPoster number